Aspirin in prevention of pre-eclampsia
Low-dose aspirin (starting between 12 and 28 weeks' gestation, and optimally before 16 weeks' gestation, and continuing until term) reduces the incidence and severity of pre-eclampsia. (1,2) Advice regarding use of aspirin in pregnancy to reduce risk of preeclampsia has been outlined by NICE (2)
Advise pregnant women at high risk of pre-eclampsia to take 75-150 mg of aspirin [*] daily from 12 weeks until the birth of the baby.
Women at high risk are those with any of the following:
- hypertensive disease during a previous pregnancy
- chronic kidney disease
- autoimmune disease such as systemic lupus erythematosus or antiphospholipid syndrome
- type 1 or type 2 diabetes
- chronic hypertension
Advise pregnant women with more than 1 moderate risk factor for preeclampsia to take 75-150 mg of aspirin[*] daily from 12 weeks until the birth of the baby. Factors indicating moderate risk are:
- first pregnancy
- age 40 years or older
- pregnancy interval of more than 10 years
- body mass index (BMI) of 35 kg/m2 or more at first visit
- family history of pre-eclampsia
- multi-foetal pregnancy
[*] Although this use is common in UK clinical practice, at the time of publication (June 2019), aspirin did not have a UK marketing authorisation for this indication. Community pharmacies cannot legally sell aspirin as a pharmacy medicine for prevention of pre-eclampsia in pregnancy in England. Aspirin for this indication must be prescribed. The prescriber should see the summary of product characteristics for the manufacturer's advice on use in pregnancy. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.
A systematic review (3) concluded that:
- daily low-dose aspirin during pregnancy was associated with lower risks of serious perinatal outcomes for individuals at increased risk for preeclampsia, without evident harms
Note - the effect of aspirin seems to be uniform across all risk groups, but its use should be targeted at high-risk groups such as those with hypertension, diabetes, renal disease, autoimmune disease, multiple pregnancy, a body mass index of >30, a maternal age of >40 years, or an interval of ≥10 years since previous pregnancy.(2,4) Meta-analyses of randomised controlled trials suggest that the benefits of aspirin may be limited to prevention of early onset rather than term disease. (5)
Reference:
- Duley L, Meher S, Hunter KE, et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2019 Oct 30;2019(10)
- NICE. Hypertension in pregnancy: diagnosis and management. NICE guideline NG133. Published June 2019, last updated April 2023
- Henderson JT, Vesco KK, Senger CA, Thomas RG, Redmond N. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021;326(12):1192-1206. doi:10.1001/jama.2021.8551
- Chappell LC, Cluver CA, Kingdom J, et al. Pre-eclampsia. Lancet. 2021 Jul 24;398(10297):341-54
- Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol. 2018 Mar;218(3):287-93.
Related pages
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.